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CD4+CD25+ regulatory T (T reg) cells are a 
unique subset of T cells that play a dominant 
role in maintaining immune tolerance (Sakaguchi 
et al., 2008). The expression of the transcrip-
tion factor Foxp3 is the genetic hallmark of   
T reg cells, and Foxp3 critically controls the 
development and inhibitory function of T reg 
cells (Fontenot et al., 2003; Hori et al., 2003; 
Khattri et al., 2003). Foxp3 functions via form-
ing complexes with other transcription factors 
such as NFAT and Runx1 (Wu et al., 2006; 
Ono et al., 2007). T reg cells can be divided 
into two subsets, naturally occurring T reg (nT 
reg) cells, and induced T reg (iT reg) cells. nT 
reg  cells  develop  via  thymic  selection  and 
constitute the circulating CD4+CD25+ T reg 
cells in the peripheral lymph tissues in normal 
mice. iT reg cells are induced from naive CD4+ 
T  cells  upon  TCR  and  TGF-  stimulation   
in vitro (Chen et al., 2003), or by tolerogenic 
antigen administration in vivo (Kretschmer 
et al., 2005). In both T reg cell populations, the 
induction of Foxp3 is subjected to epigenetic 
control, including histone modification, al-
though to a different extent (Floess et al., 2007). 
Transcription factors such as NFAT or AP-1 
play key roles in promoting Foxp3 expression 
(Mantel et al., 2006). A recent study identified 
an  enhancer  region  in  the  Foxp3  gene  that 
contains the binding sites for both NFAT and 
Smad3 in close proximity, thus providing an 
explanation for the synergistic effect of TCR 
and TGF- signaling in Foxp3 expression (Tone 
et al., 2008). However, the detailed mechanisms 
governing  the  transcriptional  regulation  of  the 
Foxp3 gene remain largely undiscovered.
The Foxo subfamily of transcription factors 
includes at least four members (Foxo1, Foxo3a, 
Foxo4, and Foxo6), and these factors are im-
portant regulators of metabolism, organ de-
velopment, cell cycle, or apoptosis in diverse 
systems (Burgering, 2008). They can act as 
either transcriptional activators or repressors 
by  forming  complexes  with  different  tran-
scriptional modulators. Their function is tightly 
regulated by the upstream phosphoinositide 
3-kinase (PI3K) and Akt pathway, which in 
turn induces the phosphorylation of Foxo fac-
tors and their nuclear export into the cytoplasm 
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The transcription factor Foxp3 is essential for optimal regulatory T (T reg) cell development 
and function. Here, we show that CD4+ T cells from Cbl-b RING finger mutant knockin or 
Cbl-b–deficient mice show impaired TGF-–induced Foxp3 expression. These T cells display 
augmented Foxo3a phosphorylation, but normal TGF- signaling. Expression of Foxo3a 
rescues Foxp3 expression in Cbl-b–deficient T cells, and Foxo3a deficiency results in 
defective TGF-–driven Foxp3 induction. A Foxo3a-binding motif is present in a proximal 
region of the Foxp3 promoter, and is required for Foxo3a association. Foxo1 exerts similar 
effects as Foxo3a on Foxp3 expression. This study reveals that Foxo factors promote 
transcription of the Foxp3 gene in induced T reg cells, and thus provides new mechanistic 
insight into Foxo-mediated T cell regulation.
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tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it   
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Cbl-b knockin mice expressing a RING finger mutant form 
in the Cbl-b locus using both in vitro and in vivo systems. 
The phosphorylation of Foxo3a and Foxo1 is up-regulated in 
these mutant T cells. Further molecular and genetic studies 
demonstrate that Foxo3a and Foxo1 act as transcription factors 
promoting Foxp3 gene expression.
RESULTS
Cbl-b regulates Foxp3 expression in vitro and in vivo
A previous study documented that Cbl-b–deficient CD4+ 
T cells are resistant to TGF-–induced conversion to Foxp3+ 
cells (Wohlfert et al., 2006). Here, we performed mecha-
nistic analyses to investigate whether the E3 ligase activity 
of Cbl-b is involved in the Foxp3 expression. Consistent 
with  the  previous  study,  Cbl-b–deficient  naive  CD4+  
T cells stimulated with TGF- displayed reduced Foxp3 
expression (Fig. 1 A). Importantly, CD4+ T cells from mice 
expressing Cbl-b with a C373A mutation in the critical 
RING finger domain (Kojo et al., 2009), showed similar 
impairment to TGF-–induced Foxp3 expression as Cbl-b–
deficient cells. The suppressive function of these in vitro 
induced T reg cells was analyzed by co-culture with CFSE-
labeled naive T cells. Although wild-type induced T reg 
cells were effective in inhibiting T effector cell division,   
T reg cells from Cbl-b–deficient or RING finger mutant 
knockin mice were much less potent in proliferative sup-
pression (Fig. 1 B).
We  further  examined  the  genera-
tion of T reg cells in vivo by perform-
ing adoptive transfer of TCR transgenic 
T cells and soluble antigen tolerization. 
Administration  of  OVA  peptide  in-
duced the generation of Foxp3+ T cells 
in mice receiving wild-type OTII trans-
genic T cells in both spleen and lymph 
nodes (Fig. 2 A); however, such increase 
was largely abrogated in recipients of 
Cbl-b–deficient OTII T cells. The ex-
periment was repeated three times and 
(Brunet et al., 1999). In the immune system, Foxo1 defi-
ciency is linked to T cell homeostasis and tolerance, partly via 
modulating IL-7 receptor expression (Kerdiles et al., 2009; 
Ouyang et al., 2009). However, the functional role of Foxo3a 
in T cells is controversial. In an early study, Foxo3a-deficient 
mice displayed autoimmunity and defective NF-B activa-
tion in T cells (Lin et al., 2004). A recent study indicates that 
Foxo3a plays an indirect role in T cell regulation via modu-
lating IL-6 cytokine production from dendritic cells (Dejean 
et al., 2009). Therefore, the exact function of Foxo3a in   
T cells remains to be elucidated.
Cbl-b is an E3 ubiquitin ligase which is essential for T cell 
activation and tolerance induction (Liu et al., 2005). Loss of 
Cbl-b results in excessive IL-2 production and proliferation 
of T cells (Bachmaier et al., 2000; Chiang et al., 2000). Cbl-b 
promotes ubiquitin conjugation to the regulatory p85 sub-
unit of PI3K, and affects downstream PI3K–Akt signaling 
(Fang and Liu, 2001). In addition, Cbl-b is up-regulated in 
anergic T cells, and it plays an essential role in T cell anergy 
induction by inhibiting critical signal transduction pathways 
(Heissmeyer et al., 2004; Jeon et al., 2004). Cbl-b interferes 
with TGF-–mediated Foxp3 expression (Wohlfert et al., 
2006). However, the exact mechanism underlying Cbl-b in 
Foxp3 expression is still lacking.
To  further  understand  Cbl-b–mediated  regulation  of   
T cell function, we performed detailed studies on the induction 
of Foxp3 expression in T cells from mice lacking Cbl-b and 
Figure 1.  The requirement of Cbl-b E3  
ligase activity in the regulation of Foxp3+  
iT reg cells. (A) Naive CD4+CD62L+CD25 T cells 
from wild-type (WT), Cbl-b–deficient (KO), and 
Cbl-b C373A knockin mice were stimulated with 
anti-CD3 and anti-CD28 in the presence of indi-
cated concentrations of TGF-. Development of 
Foxp3+ iT reg cells was assessed by FACS analysis 
after 5 d. The percentages of Foxp3-expressing 
cells are shown. Data are representative of five 
independent experiments. (B) The cells in A were 
co-cultured with CFSE-labeled CD4+CD25 T eff 
cells at a 1:1 ratio in the presence of irradiated  
T cell–depleted splenocytes and anti-CD3. CFSE 
dilution was assessed 4 d later by FACS analysis. 
Data are representative of at least three indepen-
dent experiments.JEM VOL. 207, July 5, 2010 
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role in regulating Foxp3 expression. First, we retrovirally trans-
duced into wild-type CD4 T cells with wild-type Foxo3a or 
a constitutively active Foxo3a mutant in which all three con-
served phosphorylation sites were mutated to alanines (Brunet   
et al., 1999). The effect on Foxp3 expression was then exam-
ined by performing in vitro iT reg cell differentiation assays. 
Introduction of wild-type Foxo3a increased Foxp3 expres-
sion (Fig. 4 A, top), and this effect was further augmented by 
the transduction of the constitutively active Foxo3a mutant. 
To determine whether Foxo3a acts as a downstream target of 
Cbl-b, we examined whether Foxo3a can rescue the defec-
tive Foxp3 expression in Cbl-b–deficient T cells. Retroviral 
transduction of wild-type Foxo3a increased the Foxp3 ex-
pression in Cbl-b–deficient T cells to a certain degree (Fig. 4 A, 
bottom). Notably, the constitutively active Foxo3a mutant 
augmented Foxp3 expression to the same level in wild-type 
and Cbl-b–deficient T cells. These results suggest that Foxo3a 
is a downstream target of Cbl-b.
We then sought to obtain further genetic evidence of 
the functional role of Foxo3a in T reg cell differentiation by 
analyzing T cells from Foxo3a-deficient mice. Ablation of 
Foxo3a gene did not affect the development of nT reg cells, 
as  wild-type  and  Foxo3a-deficient  mice  showed  similar 
percentage of CD25+Foxp3+ CD4+ T cells in both spleen 
and lymph nodes (Fig. 4 B). We next examined whether 
Foxo3a  deficiency  affects  Foxp3  expression  induced  by 
TGF- in iT reg cells. Ablation of Foxo3a expression re-
sulted in a marked reduction of Foxp3 expression in iT reg 
cells (Fig. 4 C), similar to that observed in Cbl-b–deficient 
T cells.
A reconstitution experiment was then performed using 
retroviral transduction of Foxo3a in Foxo3a-deficient T cells. 
Re-introduction of wild-type Foxo3a largely restored the 
Foxp3 expression in Foxo3a-deficient T cells to a degree 
similar to wild-type control cells (Fig. 4, D and E). Thus, 
significant differences were observed in the generation of 
Foxp3+ T cells between the two groups of mice (Fig. 2 B).
Foxo3a as a target in Cbl-b–regulated signaling
A previous study suggested that Cbl-b directly affects TGF- 
signaling  via  modulating  Smad2  phosphorylation  (Wohlfert   
et al., 2006). We failed to observe an effect of Cbl-b deficiency 
on the phosphorylation of either Smad2 or Smad3 under differ-
ent stimulation conditions (Fig. 3 A and Fig. S1), upon repeated 
experiments. In addition, upon TGF- stimulation T cells from 
Cbl-b C373A knockin mice showed similar levels of Smad2 or 
Smad3 phosphorylation as wild-type T cells (Fig. 3 A). We next 
sought  to  identify  potential  signaling  pathways  that  may  be   
altered by Cbl-b ablation. For this purpose, we used a panel of 
chemical inhibitors for different signaling molecules in the T reg 
cell differentiation assay. Of these inhibitors, the PI3K inhibitor 
LY294002 rescued the defective Foxp3 expression in Cbl-b–
deficient T cells (Fig. 3 B). This result was further substantiated 
by the observation that Akt phosphorylation was up-regulated in 
Cbl-b–deficient T cells, whereas the amount of phospho-Erk 
was not altered (Fig. 3 C), which is consistent with our previous 
observation (Fang and Liu, 2001).
Foxo proteins such as Foxo3a have been shown to be 
downstream targets of PI3K–Akt signal pathway (Brunet 
et al., 1999). We examined the status of Foxo3a phos-
phorylation in wild-type and mutant T cells. Cbl-b deficiency 
resulted in a marked increase of phosphorylated Foxo3a upon 
anti-CD3 plus anti-CD28 stimulation (Fig. 3 D). This increase 
was also observed in Cbl-b C373A knockin T cells (Fig. 3 D), 
suggesting that the E3 ligase activity of Cbl-b is required for 
the negative regulation of Foxo3a phosphorylation.
Foxo3a regulates Foxp3 expression
The increased phosphorylation of Foxo3a in Cbl-b mutant   
T cells prompted us to investigate whether it has a biological 
Figure 2.  Cbl-b deficiency attenuates 
Foxp3+ iT reg cell differentiation in vivo. 
Naive OTII T cells (V 5.1/5.2+) from WT and 
Cbl-b KO mice (CD45.2) were adoptively 
transferred to B6 SJL (CD45.1) mice, and the 
recipients were immunized with 10 µg of 
OVA323-339 peptide (OVAp). 5 d after immuni-
zation, Foxp3 expression in CD45.2+TCR V 
5.1/5.2+ T cells were measured. ABI, axillary, 
branchial, and inguinal lymph nodes. (A) Rep-
resentative FACS plots showing the percent-
age of Foxp3-expressing 5.1/5.2+ donor OTII  
T cells. Data are representative of three inde-
pendent experiments. (B) Statistical represen-
tation of Foxp3 induction in donor OTII T cells. 
Each dot represents an individual mouse. 
Small horizontal lines indicate the mean,  
and error bars indicate standard deviations.  
**, P < 0.01;  ***, P < 0.001. Data are from 
three independent experiments.1384 Foxo factors drive Foxp3 expression | Harada et al.
We  then  generated  individual  mutations  at  these  sites  and 
found that one of the sites proximal to the TATA box (Mut3) 
is critical for Foxo3a-driven luciferase expression, as mutation 
at this site almost completely abrogated the luciferase induction 
even with the constitutively active Foxo3a mutant (Fig. 5 B, 
bottom left). However, mutations of the other two upstream 
potential binding sites did not have any effects (Fig. 5 B, 
bottom left). Importantly, mutation at the Mut3 Foxo3a bind-
ing site did not interfere with the general promoter activity 
because Smad3 or Runx1-driven luciferase activity was not 
altered by this mutation (Fig. 5 B, bottom right), suggesting 
that Foxo3a acts specifically and independently at the Foxp3 
promoter. It should be noted that compared with the in-
duction of Foxp3 reporter activity in 293T cells (Fig. 5 A), the 
Foxp3-driven luciferase activity is relatively low in Jurkat   
T cells (Fig. 5 B). This may reflect the fact that Jurkat T cells 
have high Akt activity, which is caused by the deficiency of 
Pten (Shan et al., 2000).
To investigate whether Foxo3a directly binds to the third 
putative binding motif in the Foxp3 promoter, we performed 
Foxo3a plays an intrinsic role in regulating Foxp3 expression 
in iT reg cells.
Foxo3a directly binds to Foxp3 promoter
The transcription unit of the Foxp3 gene includes the basic pro-
moter and at least two enhancers (E1 and E2; von Boehmer 
and Nolting, 2008). To examine whether Foxo3a has a di-
rect effect on Foxp3 expression, we constructed luciferase 
reporter plasmids containing either the basic promoter, or 
a combination with one of the two enhancers, and tested the 
effect of Foxo3a in driving luciferase expression in a transient 
transfection assay. Foxo3a acted primarily at the basic pro-
moter, as addition of either enhancer only showed marginal 
effects (Fig. 5 A). Notably, the phosphorylation-defective, 
constitutively active mutant of Foxo3a was much more po-
tent in driving Foxp3 promoter activity.
Foxo subfamily of transcription factors binds to a consensus 
DNA sequence of (T/C/G)(T/C/G)T(G/A)TTTT(A/G/T; 
Paik et al., 2007). Inspection of the basic Foxp3 promoter 
revealed three putative binding sites for Foxo3a (Fig. 5 B, top). 
Figure 3.  PI3K–Akt–Foxo3a activation  
in Cbl-b–mediated regulation of Foxp3+  
iT reg cells. (A) Phosphorylation of Smad 
proteins in naive CD4+ T cells from WT, Cbl-b 
KO, and Cbl-b C373A mice. Naive CD4+ T cells 
were stimulated with anti-CD3 and anti-CD28 
in the presence of TGF- for indicated time 
periods. Whole-cell lysates were immunoblot-
ted with anti–phospho-(p)-Smad2, or anti–
p-Smad3, and reprobed with anti-Smad2/3. 
Smad2, 60 kD; Smad3, 52 kD. Data are repre-
sentative of three independent experiments. 
(B) Naive CD4+ T cells from WT and Cbl-b KO 
mice were stimulated with anti-CD3 and anti-
CD28 together with TGF- in the absence or 
presence of the PI3K inhibitor LY294002 (LY), 
the JNK inhibitor SP600125 (SP), the p38 in-
hibitor SB203580 (SB), or the calcineurin 
inhibitor cyclosporine A (Csp A). Foxp3 expres-
sion was assessed by FACS analysis after 5 d. 
The percentages of Foxp3-expressing cells are 
shown. Data are representative of three inde-
pendent experiments. (C) Naive CD4+ T cells 
were stimulated with anti-CD3 and anti-CD28 
for the indicated time periods. Whole-cell ly-
sates were immunoblotted with anti–p-Akt, 
anti-Akt, anti–p-Erk, anti-Erk2, and anti– 
-actin. Akt, 56 kD; Erk, 42/44 kD; -actin,  
45 kD. Data are representative of at least three 
independent experiments. (D) Regulation of 
Foxo3a phosphorylation by Cbl-b E3 ligase. 
Naive CD4+ T cells from WT and Cbl-b KO mice 
(top) or WT and Cbl-b C373A mice (bottom) 
were stimulated with anti-CD3 and anti-CD28 
for indicated time periods. Whole-cell lysates 
were immunoblotted with anti–p-Foxo3a, anti-
Foxo3a, and anti–-actin. Foxo3a, 95 kD;  
-actin, 45 kD. Data are representative of at 
least three independent experiments.JEM VOL. 207, July 5, 2010 
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DNA pull-down assay using biotin-labeled DNA probes. The 
wild-type motif (-TTGTTTT-) precipitated Foxo3a protein 
from TGF-–stimulated mouse T cell lysates, whereas such 
association was completely eliminated by the mutation of this 
motif (-TTGGGGT; Fig. 5 C). We then determined whether 
the  DNA-binding  domain  in  Foxo3a  is  responsible  for 
such interaction. It was found that mutation at the critical 
histidine-212 to arginine in the Foxo3a DNA binding domain 
completely blocked the association between the consensus 
DNA motif and Foxo3a (Fig. 5 D).
To further investigate whether Foxo3a binds to Foxp3 
promoter in cells, we performed chromatin immunoprecipi-
tation assay. Anti-Foxo3a immunoprecipitated the DNA 
fragments corresponding to the proximal region of Foxp3 
promoter, but not the enhancer 1 region in iT reg cells, and 
such precipitation was abolished in Foxo3a-deficient T cells 
(Fig. 5 E). Importantly, a functional DNA binding domain of 
Foxo3a is required for the induction of Foxp3 protein, as the 
H212R mutant was unable to promote Foxp3 expression in 
iT reg cells, even with the constitutively active mutation 
(Fig. 5 F). These results collectively indicate that Foxo3a 
induces Foxp3 gene expression by directly binding to Foxp3 
basic promoter.
Foxo1 has similar function in Foxp3 gene induction
Because Foxo1, a close homologue of Foxo3a, is also in-
volved in T cell regulation (Kerdiles et al., 2009; Ouyang 
et al., 2009), we next examined whether it also promotes 
Foxp3 transcription. First we observed the up-regulation of 
Foxo1  phosphorylation  in  Cbl-b–deficient  CD4+  T  cells 
(Fig. 6 A) and in Cbl-b RING finger mutant knockin T cells 
(Fig.  6  B).  We  then  performed  shRNA-mediated  Foxo1 
knockdown in primary mouse CD4+ T cells and examined   
in vitro TGF-–induced Foxp3 induction. Retroviral trans-
duction of two Foxo1 shRNAs impaired Foxp3 expression as 
compared with the control cells (Fig. 6 C). The effect of shRNAs 
on Foxo1 expression was determined by immunoblotting, 
showing that both shRNAs were effective in reducing Foxo1 
Figure 4.  Foxo3a regulates Foxp3+ iT reg cell differentiation.  
(A) Naive CD4+ T cells from WT and Cbl-b KO mice were stimulated with 
anti-CD3 and anti-CD28 for 2 d and retrovirally transduced with control-
IRES-GFP (GFP), Foxo3a WT-IRES-GFP (Foxo3a WT), or Foxo3a 3A-IRES-GFP 
(Foxo3a 3A). After infection, TGF- was added and Foxp3 expression was 
assessed 3 d later by FACS analysis. The percentages of Foxp3-expressing 
cells in gated GFP-positive cells are shown. Data are representative of 
four independent experiments. (B) nT reg cells in the spleen and lymph 
nodes of Foxo3a KO mice. The spleen and the lymph node cells from WT 
and Foxo3a KO mice were stained with anti-CD4, anti-CD25, and anti-
Foxp3. The percentages of Foxp3-expressing cells in CD4 T cells are 
shown. Data are representative of three independent experiments.  
(C) Naive CD4+ T cells were stimulated with anti-CD3 and anti-CD28 in 
the presence of indicated concentrations of TGF- for 3 d. Foxp3 expres-
sion was assessed by FACS analysis. The percentages of Foxp3-expressing 
cells in gated CD4 T cells are shown. Data are representative of five 
independent experiments. (D) Naive CD4 T cells from WT and Foxo3a KO 
mice were stimulated with anti-CD3 and anti-CD28 for 2 d and retro-
virally transduced with control-IRES-GFP (GFP) or Foxo3a WT-IRES-GFP 
(Foxo3a WT). 1 d after infection, TGF- was added, and Foxp3 expression 
was assessed 3 d later by FACS analysis. A representative of three repeated 
experiments. (E) The percentages of Foxp3-expressing cells in GFP-positive 
cells as shown in D are calculated and shown as mean ± SD of three 
independent experiments. Statistical significance of the data were  
evaluated by unpaired two-tailed Student’s t test.
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Figure 5.  Foxo3a directly binds to the Foxp3 promoter. (A) 293T cells were transfected with luciferase reporter plasmids containing the Foxp3 
promoter, the promoter and the Foxp3 enhancer 1 (E1), or the promoter and the Foxp3 enhancer 2 (E2), together with an empty, Foxo3a WT, or Foxo3a 3A 
expression vector. Bars show the mean relative luciferase unit (RLU) ± SD as arbitrary light units of three independent experiments. (B, top) Schematic 
structure of the Foxp3 promoter region and mutated sequence of the Foxp3 promoter. (bottom) Jurkat cells were transfected with luciferase reporter plas-
mids containing the Foxp3 promoter and the Foxp3 enhancer 1 or the Foxp3 promoter with Foxo3a binding site mutated and the Foxp3 enhancer 1 (WT, 
Mut1, Mut2, and Mut3) together with an empty, Foxo3a WT, Foxo3a 3A, Runx1, or Smad3 expression vectors. 24 h after transfection, these cells were stim-
ulated with anti-CD3 and anti-CD28 for 8 h. Bars show the mean RLU ± SD as arbitrary light units of three independent experiments. (C) Pull-down assay 
of Foxo3a binding to a WT or mutated (Mut3) sequence of the Foxp3 promoter. Cell lysates from naive CD4 T cells stimulated with anti-CD3, anti-CD28, and 
TGF- were mixed with biotinylated DNA probes. The labeled DNA probes were precipitated with streptavidin-agarose beads, and the precipitates were 
subjected to SDS-PAGE, followed by immunoblotting with anti-Foxo3a. Input represents 5% of the total amount used for precipitation. Foxo3a, 95 kD. Data 
are representative of three independent experiments. (D, top) Schematic structure of Foxo3a WT and H212R mutant. (bottom) 293T cells were transfected 
with myc-tagged Foxo3a WT or H212R mutant. The cell lysates were mixed with biotinylated DNA probes encoding WT or Mut3 Foxp3 promoters and pull-
down assay was performed as in C. Foxo3a was detected by immunoblotting with anti-myc to detect myc-tagged Foxo3a proteins. Foxo3a, 95 kD. Data are 
representative of three independent experiments. (E) Chromatin immunoprecipitation analysis of Foxo3a binding to the Foxp3 promoter region. Naive CD4  
T cells were unstimulated or stimulated with anti-CD3 and anti-CD28 together with TGF-. Cell lysates were immunoprecipitated with anti-Foxo3a or control 
IgG. Immunoprecipitates from WT and Foxo3a KO T cells were analyzed by quantitative real-time PCR, using primers corresponding to Foxp3 pro-
moter, its enhancer 1, and a nonspecific Actin promoter as a control. The results were presented as fold of template enrichment in immunoprecipitates of 
anti-Foxo3a relative to those of control IgG (mean and SD of three independent experiments). (F) Naive CD4+ T cells were stimulated with anti-CD3 and 
anti-CD28 for 2 d and retrovirally transduced with control-IRES-GFP (GFP), Foxo3a WT-IRES-GFP (Foxo3a WT), Foxo3a 3A-IRES-GFP (Foxo3a 3A), or 
Foxo3a 3A H212R-IRES-GFP (Foxo3a 3A H212R). After infection, TGF- was added and Foxp3 expression was assessed 3 d later by FACS analysis. The  
percentages of Foxp3-expressing cells in GFP positive cells are shown. Data are representative of at least three independent experiments.JEM VOL. 207, July 5, 2010 
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phosphorylation of Smad2, which impairs Foxp3 expression 
in iT reg cells (Wohlfert et al., 2006). However, our repeated 
experiments convincingly told us that this might not be the 
case. Although we cannot exclude the possibility that Cbl-b 
may play an indirect role in regulating TGF- signaling, at 
present we would favor the pathway that Cbl-b regulates 
Foxp3 expression via modulating PI3K–Akt–Foxo3a signaling 
as documented in this study. The present study is consistent 
with our original finding that Cbl-b promotes ubiquitination 
of p85, which is the regulatory subunit of PI3-K, and affects 
downstream  Akt  phosphorylation  (Fang  and  Liu,  2001). 
More importantly, we extended the previous studies by show-
ing that the E3 ligase activity of Cbl-b is critical for such 
regulation, as T cells containing the ligase-inactive RING 
finger mutant exhibited a similar phenotype as Cbl-b–deficient 
T cells in regard to Foxo3a/Foxo1 phosphorylation and in 
vitro Foxp3 induction. Therefore, the present study identi-
fies a unique mechanism by which the Cbl-b E3 ligase regu-
lates the development and function of iT reg cells. It should 
be noted that this study is consistent with the previous obser-
vation that Cbl-b only regulates the Foxp3 expression in   
iT reg cells, but not in nT reg cells (Wohlfert et al., 2006). 
One possible explanation is that Cbl-b plays a dominant role 
in peripheral mature T cells, but not during early thymic de-
velopment (Bachmaier et al., 2000; Chiang et al., 2000). 
Another possibility is the overlapping role of Cbl-b with   
expression (Fig. 6 D). Similarly, retroviral transduction of 
Foxo1 in mouse CD4+ T cells augmented Foxp3 expression 
to the similar extent as Foxo3a (Fig. 6 E). Finally, we dem-
onstrated that Foxo1 bound to the wild-type, but not the 
mutated, Foxo3a binding motif in the DNA pull-down assay 
(Fig. 6 F). The results suggest that Foxo1 plays a role similar 
to that of Foxo3a in Foxp3 induction.
DISCUSSION
By using both in vitro and in vivo genetic and biochemical ap-
proaches, we have provided convincing evidence that Foxo3a 
acts as a transcription factor influencing Foxp3 gene expres-
sion. The phosphorylation of Foxo3a is up-regulated in Cbl-b– 
deficient or the ligase-inactive RING finger mutant T cells. 
Foxo3a expression increases Foxp3 expression and rescues the 
defective Foxp3 expression in Cbl-b mutant T cells. T cells 
deficient in Foxo3a are resistant to TGF-–induced Foxp3 in-
duction, whereas retroviral reconstitution of Foxo3a restores 
such defect. Finally, a functional Foxo binding motif is present 
in the basic promoter of Foxp3, and a direct protein–DNA in-
teraction is necessary for Foxp3 gene transcription. In addition, 
Foxo1 has a function similar to that of Foxo3a. We thus con-
clude that transcription factors Foxo3a and Foxo1 couple the 
Cbl-b E3 ligase to the induction of Foxp3 in iT reg cells.
Our current findings seem to be at odds with a previous 
publication showing that Cbl-b regulates TGF-–induced 
Figure 6.  Foxo1 regulates Foxp3 expres-
sion. (A and B) Naive CD4+ T cells from WT 
and Cbl-b KO mice (A) or WT and Cbl-b C373A 
mice (B) were stimulated with anti-CD3 and 
anti-CD28 for indicated time periods. 
Whole-cell lysates were immunoblotted with 
anti–p-Foxo1, anti-Foxo1 (75 kD), and anti–
-actin (45 kD). Data are representative of 
three independent experiments. (C) Naive 
CD4+ T cells were stimulated with anti-CD3 
and anti-CD28 for 2 d and transduced with 
retroviruses encoding Foxo1-specific shRNAs 
(shRNA1 or shRNA2) or with empty LMP 
vector (control). After 24 h, TGF- was added 
and Foxp3 expression was assessed 3 d later 
by FACS analysis. Cells were treated with 
puromycin for last 48 h. The percentages of 
Foxp3-expressing cells in GFP-positive cells 
are shown. Data are representative of three 
independent experiments. (D) Cell lysates in 
(C) were immunoblotted with anti-Foxo1  
(75 kD), anti-Foxo3a (95 kD), and anti--actin 
(45 kD). Data are representative of three inde-
pendent experiments. (E) Naive CD4 T cells 
were stimulated with anti-CD3 and anti-
CD28 for 2 d and retrovirally transduced with 
control-IRES-GFP (GFP), Foxo1 WT-IRES-GFP 
(Foxo1 WT), or Foxo3a WT-IRES-GFP (Foxo3a 
WT). After infection, TGF- was added and Foxp3 expression was assessed 3 d later by FACS analysis. The percentages of Foxp3-expressing cells in GFP-
positive cells are shown. Data are representative of four independent experiments. (F) Pull-down assay of Foxo1 binding to WT or mutated (Mut3) se-
quence of the Foxp3 promoter. DNA pull-down assay was performed using biotinylated DNA probes. The precipitates were subjected to SDS-PAGE, 
followed by immunoblotting with anti-Foxo1 (75 kD). Data are representative of at least three independent experiments.1388 Foxo factors drive Foxp3 expression | Harada et al.
(Dejean et al., 2009; Kerdiles et al., 2009; Lin et al., 2004; 
Ouyang et al., 2009), the possibility exists that these Foxo 
members function in a redundant manner. We indeed ob-
served that Foxo1 phosphorylation is also regulated in Cbl-b 
mutant T cells and shRNA knockdown of Foxo1 reduces 
Foxp3 expression in iT reg cells. Although the functional role 
Foxo1 or Foxo3a remains unclear in the development of nT reg 
cells (Dejean et al., 2009; Ouyang et al., 2009 and this study), 
it is quite possible that the overlapping function of the Foxo 
family members affects the development of both nT reg cells 
and iT reg cells. Nevertheless, the present study provided 
compelling evidence that Foxo transcription factors play an 
intrinsic role in T cells by regulating the Foxp3 expression at 
the transcription level.
In this study, we emphasize that Cbl-b regulates iT reg 
cells via modulating the PI3K–Akt–Foxo pathway in an E3 
ligase–dependent manner. Previous studies have shown that 
Cbl-b may target different substrates in different cell types or 
under different physiological conditions. For example, Cbl-b 
is shown to promote the ubiquitination of PLC-1 and/or 
PKC in anergic T cells, which blocks T cell activation upon 
subsequent effective T cell stimulation (Heissmeyer et al., 2004; 
Jeon et al., 2004). However, in anergic natural killer T cells, 
Cbl-b primarily induces the ubiquitination of CARMA1, and 
affects NF-B–mediated IFN- production (Kojo et al., 2009). 
We propose that Cbl-b acts as a gatekeeper of lymphocyte 
activation by targeting different substrates to ensure that the 
immune  tolerance  is  properly  maintained.  Understanding 
such detailed mechanisms may benefit the therapeutic inter-
vention in human immune diseases.
MATERIALS AND METHODS
Mice. C57BL/6 mice were obtained from The Jackson Laboratory. B6 SJL 
(CD45.1) mice were obtained from Taconic. Cbl-b–deficient mice on B6 
background were obtained from H. Gu (Columbia University, New York, 
NY). Cbl-b C373A knockin mice were provided by W. Langdon (Univer-
sity of West Australia, Crawley, WA, Australia; Kojo et al., 2009), OVA323-329-
specific TCR transgenic OT-II mice (Jeon et al., 2004), and Foxo3a-deficient 
mice (Castrillon et al., 2003) were previously described. All mice were 
housed in specific pathogen–free conditions. The experiment protocols 
were approved by members of the Institutional Animal Care and Use Com-
mittee of the La Jolla Institute for Allergy and Immunology.
Separation of cells. CD4+CD62L+CD25 naive T cells and CD4+CD25 
effector T (T eff) cells were separated by MACS beads (Miltenyi Biotec) ac-
cording to the manufacturer’s instruction. The purity of separated cell popu-
lation was >93% for CD4+CD62L+CD25 T cells and >95% for CD4+CD25 
T eff cells. T cell–depleted splenocytes were obtained by depleting T cells by 
using anti-CD4 and anti-CD8 microbeads (Miltenyi Biotec).
In vitro T reg cells generation. CD4+CD62L+CD25 T cells (2 × 105) 
from wild-type C57BL/6, Cbl-b–deficient, Cbl-b C373A, wild-type FVB/
NJ, or Foxo3a-deficient mice were stimulated with plate-bound anti-CD3 
(145-2C11) and soluble anti-CD28 (PV-1; provided by R. Abe, Tokyo Univer-
sity of Science, Noda, Chiba, Japan) together with indicated concentra-
tions of rhTGF- (PeproTech) in 96-well flat-bottomed plates for 3 d, or cells 
were cultured with rhIL-2 for additional 2 d. For inhibitor experiments, 
LY294002 (for PI3K, 10 µM), SP600125 (for JNK, 10 µM), SB203580 
(for p38, 10 µM), or cyclosporine A (for calcineurin, 20 ng/ml) was added 
to the culture. All inhibitors were purchased from Calbiochem.
c-Cbl; deficiency of either isoform may not lead to a signifi-
cant effect in early stage nT reg cells development. Future 
studies are needed to test such possibilities.
One of the downstream targets of Akt is the mammalian 
target of rapamycin (mTOR; Hay and Sonenberg, 2004). 
Two recent studies documented that mTOR forms the PI3K– 
Akt–mTOR axis in regulating Foxp3 expression (Haxhinasto 
et al., 2008; Sauer et al., 2008). The involvement of mTOR 
in the differentiation of iT reg cells was further supported 
by a more recent publication showing that T cells lacking 
mTOR kinase differentiate into iT reg cells with only TCR 
stimulation in the absence of TGF- (Delgoffe et al., 2009). 
Therefore, the possibility arises that Cbl-b regulates Foxp3 
expression via modulating the mTOR pathway. However, 
detailed examination of the mTOR-deficient T cells showed 
that only the mTOR complex 2 (TORC2), which is less sen-
sitive to rapamycin, but not the rapamycin-sensitive TORC1, 
is involved in Foxp3 expression (Delgoffe et al., 2009). It is 
suggested that TORC2 exerts its function via modulating the 
activation of Akt (Guertin et al., 2006) to form a positive 
regulatory  loop.  A  similar  mechanism  may  operate  here  if 
Foxo3a is a downstream target of both Akt and mTOR path-
ways in Cbl-b–regulated Foxp3 expression in iT reg cells.
Although an earlier study suggested that the basic Foxp3 
promoter contains NFAT binding site (Mantel et al., 2006), 
a recent study indicated that a functional NFAT binding site 
lies in an enhancer region, with close proximity to the Smad3 
binding motif (Tone et al., 2008). This raises the issue of 
whether the transcriptional activity of the basic promoter is 
regulated by other transcription factors. Several recent studies 
have documented that the Runx transcription factors are 
critically involved in induction and suppressive function of 
T reg cells (Bruno et al., 2009; Kitoh et al., 2009; Klunker 
et al., 2009; Rudra et al., 2009), with the identification of 
direct binding sites, including in the Foxp3 basic promoter 
(Klunker et al., 2009; Rudra et al., 2009). We reported that 
TIEG1, a TGF-–induced early gene product, is involved in 
Foxp3 gene expression, via ubiquitination-dependent modi-
fication by the E3 ligase Itch (Venuprasad et al., 2008). Inter-
estingly, the putative Foxo3a binding site close to the TATA 
box seems to play a dominant role in driving Foxp3 gene 
transcription. This unusual binding for Foxo3a was also found 
in the promoter of Atrogen-1 gene (Sandri et al., 2004), even 
though the functional significance remains unclear. It is still 
possible that Foxo3a binds to other sites/regions of Foxp3 
gene locus. Nevertheless, the description of Foxo3a as a tran-
scription factor directly acting at the basic promoter thus 
provides  additional  mechanisms  for  the  transcriptional 
control of the Foxp3 gene.
The fact that the highly related Foxo family members 
serve as a common target of PI3K–Akt pathway suggests that 
they are functionally redundant, which is supported by ge-
netic studies that conditional deletion of Foxo1, 3a, and 4 
results in tumor formation and alteration of common down-
stream targets (Paik et al., 2007). Although genetic deletion of 
Foxo1 or Foxo3a resulted in different phenotypes in T cells JEM VOL. 207, July 5, 2010 
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ATTATCCTTGAAGTAGGGCACGCTGCCTACTGCCTCGGA-3; 
Foxo1 shRNA2, 5-TGCTGTTGACAGTGAGCGCCCATGGACAA-
CAACAGTAAATTAGTGAAGCCACAGATGTAATTTACTGTTGTT-
GTCCATGGATGCCTACTGCCTCGGA-3.
Retroviral transduction. Plat-E cells were transfected with 3 µg of   
pMX-IRE-GFP vector or LMP vector with 9 µl of TransIT-LT1 (Mirus). 
At 48 h, the culture supernatant containing retrovirus was collected. Naive 
CD4+CD62L+CD25 T cells were stimulated with plate-bound anti-CD3 
and soluble anti-CD28. At 48 h, CD4 T cells were infected with retrovirus 
together with 5 µg/ml polybrene by centrifuging cells at 2,000 rpm for   
60 min at room temperature. After infection, TGF- was added and T cells 
were cultured for additional 3 d. Cells were cultured with 100 U/ml human 
rIL-2 for the last 2 d.
Reporter assay. 293T or Jurkat T cells were transfected with indicated 
amounts of Foxp3 promoter luciferase reporter plasmid together with 0.5 µg of 
Foxo3a WT, Foxo3a 3A, Smad3, or Runx1 expression vectors, and 0.05 µg 
of -gal expression vector by using 3 µl of TransIT-LT1 for 293T cells, or 
electroporation for Jurkat T cells. 24 h later, cells were resuspended in 100 µl 
of lysis buffer (100 mM potassium phosphate buffer, pH 7.8, 0.2% Triton 
X-100, and 1 mM DTT) and incubated at room temperature for 10 min. 
After centrifugation, 30 µl of the supernatant was used with 100 µl of luciferase 
assay reagent (BD). Luminescence was measured with a Monolight 2010   
(Analytical Luminescence Laboratory).
DNA pull-down assay. A DNA fragment containing wild-type or mutant 
Foxo-binding site was amplified by PCR using a 5-biotin-labeled for-
ward primer. Primer sequences were as follows: DNA pull-down forward, 
5-ATTAGAAGAGCGAGGTCTGCGGC-3’; DNA pull-down reverse, 
5-CTTGGTGAAGTGGACTGCTAGAG-3’.  The  biotinylated  probes 
(1.5 µg) was mixed with cell lysates in 400 µl of a binding buffer (25 mM 
Hepes, pH7.9, 50 mM NaCl, 1 mM MgCl2, 1 mM DTT, 2 µg polydI-dC) 
for 2 h at 4°C. Then 20 µl of streptavidin-agarose beads (Invitrogen) was 
added and incubated for an additional 1 h. The streptavidin-agarose beads 
were washed five times with the binding buffer, and then SDS-sample buffer 
was added. The complexes were subjected to SDS-PAGE, followed by 
immunoblotting with anti-Foxo3a, anti-Foxo1, or anti-Myc.
Chromatin immunoprecipitation assay. Cells were cross-linked by 
addition of fresh 1% formaldehyde in PBS for 10 min at room temperature, 
followed by quenching with 135 mM glycine. Fixed cells were resuspended 
in a lysis buffer (10 mM Hepes, pH 7.9, 0.5% IGEPAL-CA630, 1.5 mM 
MgCl2, and 10 mM KCl) with protease inhibitor for 15 min on ice. After   
centrifugation, the cell pellet was resuspended in nuclear lysis buffer (50 mM 
Tris, pH 8.1, 10 mM EDTA, 1% SDS) with protease inhibitor for 10 min on 
ice and sonicated 7 times for 30 s, and then the lysates were cleaned by 
centrifugation. The sheared DNA was diluted 10-fold in a dilution buffer 
(0.01% SDS, 16.7 mM Tris-Hcl, pH 8.1, 1.2 mM EDTA, and 167 mM 
NaCl). The chromatin solution was incubated with 4 µg of control rabbit 
IgG (Santa Cruz Biotechnology, Inc.), anti-Foxo3a (Santa Cruz Biotechnol-
ogy, Inc.) or anti-Foxo3a (Cell Signaling Technology), and 20 µl of fully 
suspended protein A magnetic beads (Millipore) overnight at 4°C. The beads 
were washed sequentially with low-salt wash buffer (0.1% SDS, 1% Triton 
X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), high-salt 
wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 
pH 8.1, and 500 mM NaCl), LiCi wash buffer (0.25 M LiCl, 1% IGEPAL-
CA630, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1, and 1% deoxycholic 
acid), and TE butter. Precipitates were extracted and cross-linking was 
reversed with 1% SDS, 0.1 M NaHCO3, 200 µg/ml proteinase K by heat-
ing at 62°C for 2 h with shaking. The DNA mixture was purified using 
a PCR purification kit (QIAGEN). The purified DNA was used for real-
time PCR with iTaq SYBR green supermix with ROX (Bio-Rad Labo-
ratories). Primer sequences were as follows: Foxp3 promoter forward,   
5-GGATTATTAGAAGAGCGAGGTCTGC-3’; Foxp3 promoter reverse, 
T reg cell suppression assay. Naive CD4+CD25 T cells (105 cells) were 
labeled with 5 µM CFSE (Invitrogen) for 10 min at 37°C in PBS/0.1% BSA, 
and were then cocultured with in vitro induced T reg cells (105 cells) from 
WT, Cbl-b–deficient, or Cbl-b C373A mice in the presence of T cell–
depleted splenocytes (5 × 105 cells) and soluble anti-CD3. 4 d later, cells 
were harvested, and CFSE dilution was measured by FACS analysis.
In vivo induction of iT reg cells. Naive CD4+CD62L+CD25 T cells 
were purified from spleen of WT or Cbl-b–deficient OTII mice, and 1–2 × 
106 cells were injected i.v. to B6.SJL (CD45.1) mice. The next day, the 
recipient mice were immunized with soluble chicken OVA323-339 peptide 
(10 µg; AnaSpec). 5 d after administration of OVA peptide, cells were col-
lected from secondary lymphoid tissues (axillary, branchial, inguinal, and 
mesenteric lymph nodes and spleen).
Flow cytometry. Antibody against TCRV 5.1/5.2 was purchased from 
BD, antibodies against CD4 and CD25 were purchased from BioLegend, 
and antibodies against Foxp3, CD62L, and CD45.2 were purchased from 
eBioscience. Intracellular Foxp3 staining was performed with Cytofix/
Cytoperm reagent (BD).
Immunoprecipitation and immunoblotting. Antibodies to phospho-
Smad2,  phospho-Smad3,  phospho-Akt  (Ser473),  Akt,  phospho-Erk1/2, 
phospho-Foxo3a (Ser253), Foxo3a, phospho-Foxo1 (Ser256), and Foxo1 
were purchased from Cell Signaling Technology. Antibodies to Smad2/3, 
Erk2, and Myc were purchased from Santa Cruz Biotechnology. Anti– 
-actin was obtained from MP Biomedicals. Cells were lysed with 1 x NP-40 
lysis buffer (1% NP-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM 
EDTA, 50 mM NaF, 2 mM Na3VO4, and 10 µg/ml each of aprotinin and 
leupeptin) or were lysed with 1 x SDS sample buffer (50 mM Tris-HCl,   
pH 6.8, 100 M DTT, 2% SDS, and 10% glycerol). Samples were subjected 
to 8–10% SDS-PAGE and electrotransferred onto polyvinylidene difluoride 
membranes (Millipore). Membranes were probed with the indicated primary 
antibodies, followed by HRP-conjugated secondary antibodies. Membranes 
were then washed and visualized with the enhanced chemiluminescence 
detection system (ECL; GE Healthcare). When necessary, membranes were 
stripped by incubation in stripping buffer (Thermo Fisher Scientific) for   
15 min with constant agitation, washed, and then reprobed with various 
other antibodies.
Plasmids. The Foxp3 promoter (490/+184), enhancer 1 (+1987/+2736), 
and enhancer 2 (+3,665/+4,823) regions were amplified by PCR from   
genomic DNA of B6 mice by using the following primers: Foxp3 promoter   
forward, 5-CTTCCCATTCACATGGCAGGCTTC-3; Foxp3 promoter 
reverse, 5-CAAAGTCCTTACCTGGAGTGGCTG-3; Foxp3 enhancer1 
forward, 5-TTGTGCTTTGTAATGCATGTG-3; Foxp3 enhancer1 reverse, 
5-GGACTGATGCTGCTAGGTG-3; Foxp3 enhancer 2 forward, 5-TTG-
TCCCAGGAGAGC-3; and Foxp3 enhancer 2 reverse, 5-CCCATATG-
GCTGGAC-3. The PCR products were cloned into the pGL3 basic vector 
(Promega Biotech). Mutations of three putative Foxo3a binding sites in the 
Foxp3 promoter region were generated by oligonucleotide-directed site-
specific mutagenesis. The following primers and their complementary strands 
were used: Mut1, 5- CTGACTCTACACACTTTTGGGGAAGAAATTG-
TGGTTTCTC-3; Mut2, 5-GTGAGGGGAAGAAATCATAGGGTCA-
GATGACTTGTAAAGGG-3; and Mut3, 5-CGGTATAAAAGCAAA-
GTTGGGGTTGATAATGTGGCAGTTTCC-3.
The Foxo3a wild-type, a mutant with three phosphorylation sites mu-
tated to alanines (Foxo3a 3A), and Foxo1 cDNAs were subcloned in the 
pcDNA3 myc (Invitrogen) and pMX-IRES-GFP vectors, respectively. The 
DNA binding-defective mutant of Foxo3a 3A was generated by making 
point mutation at histidine 212 to arginine (H212R). To construct Foxo1 
shRNA vector, oligonucleotides were cloned in the LMP vector according 
to manufacture’s protocol (Open Biosystems). Oligonucleotide sequences 
were  the  following:  Foxo1  shRNA1,  5-TGCTGTTGACAGTGAGC-
GACGTGCCCTACTTCAAGGATAATAGTGAAGCCACAGATGT-1390 Foxo factors drive Foxp3 expression | Harada et al.
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